177Lu-JH04

N/A

Report date: 2025/11/20 11:37:54

Base Information

Drug Name177Lu-JH04

Drug Alias Name177Lu-JH04

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionPositron-emission tomography enhancersIonising radiation emittersFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesFirst Affiliated Hospital Of Fujian Medical University

China Registration ClassN/A

Develop Information

Active CompaniesFirst Affiliated Hospital Of Fujian Medical University

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A